Literature DB >> 19453364

Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours.

K Shiomitsu1, C L Johnson, D E Malarkey, A F Pruitt, D E Thrall.   

Abstract

Epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) signalling pathways play a role in carcinogenesis. Inhibition of EGF receptor (EGFR) and of VEGF is effective in increasing the radiation responsiveness of neoplastic cells both in vitro and in human trials. In this study, immunohistochemical evaluation was employed to determine and characterize the potential protein expression levels and patterns of EGFR and VEGF in a variety of canine malignant epithelial nasal tumours. Of 24 malignant canine nasal tumours, 13 (54.2%) were positive for EGFR staining and 22 (91.7%) were positive for VEGF staining. The intensity and percentage of immunohistochemically positive neoplastic cells for EGFR varied. These findings indicate that EGFR and VEGF proteins were present in some malignant epithelial nasal tumours in the dogs, and therefore, it may be beneficial to treat canine patients with tumours that overexpress EGFR and VEGF with specific inhibitors in conjunction with radiation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453364     DOI: 10.1111/j.1476-5829.2009.00178.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  9 in total

1.  EGF Level in Hepatoid Gland Adenomas and Hepatoid Gland Epitheliomas in Dogs After Administering Tamoxifen.

Authors:  Aleksandra Sobczyńska-Rak; Beata Żylińska; Łukasz Jarosz; Adam Brodzki; Marcin Tatara
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

2.  Elevated EGF Levels in the Blood Serum of Dogs with Periodontal Diseases and Oral Tumours.

Authors:  Aleksandra Sobczyńska-Rak; Beata Żylińska; Izabela Polkowska; Tomasz Szponder
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

Review 3.  Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.

Authors:  Sandeep S Patil; Ivaylo Gentschev; Ingo Nolte; Gregory Ogilvie; Aladar A Szalay
Journal:  J Transl Med       Date:  2012-01-04       Impact factor: 5.531

4.  EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?

Authors:  Rossella Terragni; Andrea Casadei Gardini; Silvia Sabattini; Giuliano Bettini; Dino Amadori; Chiara Talamonti; Massimo Vignoli; Laura Capelli; Jimmy H Saunders; Marianna Ricci; Marianna Ricci; Paola Ulivi; Paola Ulivi
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

5.  Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics.

Authors:  Zeenat Mirza; Hans-Juergen Schulten; Hasan Ma Farsi; Jaudah A Al-Maghrabi; Mamdooh A Gari; Adeel Ga Chaudhary; Adel M Abuzenadah; Mohammed H Al-Qahtani; Sajjad Karim
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

6.  Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.

Authors:  Fernanda B Mantovani; Jodi A Morrison; Anthony J Mutsaers
Journal:  BMC Vet Res       Date:  2016-05-31       Impact factor: 2.741

7.  Comparison of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) immunohistochemical expression and outcomes in canine nasal carcinomas treated with radiation therapy.

Authors:  Dah-Renn Fu; Tsuyoshi Kadosawa
Journal:  J Vet Med Sci       Date:  2022-07-15       Impact factor: 1.105

8.  Epidermal growth factor receptor expression in canine transitional cell carcinoma.

Authors:  Kiwamu Hanazono; Shinya Fukumoto; Yoshio Kawamura; Yoshifumi Endo; Tsuyoshi Kadosawa; Hidetomo Iwano; Tsuyoshi Uchide
Journal:  J Vet Med Sci       Date:  2014-09-16       Impact factor: 1.267

9.  Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.

Authors:  Caitlin M Heaton; Arthur F A Fernandes; Paulo C Jark; Xuan Pan
Journal:  J Vet Intern Med       Date:  2020-01-24       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.